This content is from:xinyabo体育
Revenge of the Arbs
After several years of meager returns, merger arbitrageurs are set to prove the skeptics wrong.
The impending sale of cardiovascular-device maker Guidant Corp. has been one wild ride for merger arbitrageurs. When Johnson & Johnson announced in December 2004 that it had agreed to buy Guidant for $76 a share in cash and stock, the arbs piled into the $25.4 billion deal. They knew that
To continue reading,subscribe nowto Premium Journalism. Already a subscriber?Login.